Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sandoz’s Rituxan Biosimilar Adds Nephrotic Syndrome Use
Sandoz said on March 7 that it has earned Japanese regulatory approval for its biosimilar version of Rituxan (rituximab) for an additional indication of “refractory nephrotic syndrome (frequently relapsing or steroid-dependent cases).”The label was broadened for Rituximab BS Intravenous Infusion…
To read the full story
Related Article
- Rituxan Biosimilar Expands Nephrotic Syndrome Indication in Japan
April 24, 2026
- Sandoz’s Rituximab Biosimilar Adds Pediatric ITP Indication
December 26, 2024
- Kyowa Kirin/Sandoz’s Rituxan Biosimilar Expands Label
November 19, 2020
BUSINESS
- AbbVie Japan Says Sales-Doubling Plan on Track as Revenue Climbs 13.5%
June 3, 2026
- FunPep, Crafton Join Forces on Therapeutic mRNA Vaccines
June 3, 2026
- Shionogi’s Xocova Scores US FDA Nod for COVID-19 PEP
June 3, 2026
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…